Amycretin

Synonyms: ALT-801, GLP-1/Glucagon receptor agonist, dual incretin agonist

Amycretin is a synthetic peptide dual agonist engineered to activate both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Altimmune, this investigational compound is designed to combine the glucose-regulating and appetite-suppressing effects of GLP-1 with the energy-expending effects of glucagon, offering a promising approach to metabolic disorders such as obesity and type 2 diabetes.

Currently in clinical development, Amycretin has shown encouraging results in early-stage trials, including significant reductions in body weight and improvements in metabolic parameters. Its peptide structure allows for subcutaneous administration, and it is being investigated for chronic weight management and type 2 diabetes.

Function

• GLP-1 receptor agonism: Enhances insulin secretion and promotes satiety.
• Glucagon receptor agonism: Increases energy expenditure and hepatic glucose output.
• Weight management: Reduces body weight through combined effects on appetite and metabolism.
• Glycemic control: Improves blood glucose levels in type 2 diabetes.

Source & Standardization

• Source: Synthetic peptide produced via solid-phase peptide synthesis (SPPS).
• Extraction: Purified by preparative HPLC.
• Standardization: Purity ≥98% by HPLC.
• Forms: Lyophilized powder.
• Applications: Research use in obesity and diabetes studies.

Specifications

Documentation & Supply

• MOQ: 5 g
• Lead time: 1-2 weeks after order confirmation.
• Documentation: COA, MSDS, TDS provided.
• Packaging: Sealed vials or custom packaging available.

Request For Quote

• Our Address: 280 Main Street, Xian, Shaanxi, China
• LyvBio Co., Ltd. — Email: info@lyvbio.com